Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 43

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 43
---
 discussion and analysis is intended to enhance your understanding of the information provided in the compensation tables below and to provide additional context regarding our overall executive compensation program.

#### Executive Summary
We are a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies targeting lung and gastrointestinal ("GI") cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications. We expect our clinical-stage portfolio to continue to expand and to include molecules targeting immuno-oncology, cancer cell-intrinsic and immunological pathways. Our vision is to create, develop and commercialize highly differentiated therapies that have a meaningful impact on patients.

#### 2024 Say-on-Pay Vote
At our 2024 annual meeting of stockholders, approximately 96% of the votes cast on the say-on-pay proposal voted in support of the compensation paid to our named executive officers for 2023. While this vote was only advisory and not binding, the Compensation Committee believes that the 2024 stockholder vote generally endorsed our compensation philosophy and the decisions made for 2023. As such, we did not make any significant changes to our core compensation philosophies and practices in 2024. We hold a say-on-pay vote on an annual basis.

### 2024 Business Highlights
The following summarizes key highlights of our corporate performance during our fiscal year ended on December 31, 2024:

◦ Advanced our late-stage programs developing domvanalimab and zimberelimab towards potential commercialization by completing enrollment for STAR-221 several months ahead of schedule.

◦ Generated and presented compelling data from ARC-20, our Phase 1 study evaluating casdatifan across multiple cohorts. The strength of this data supports further development of casdatifan, and we hope to leverage the interest generated by ARC-20 as we initiate PEAK-1, our Phase 3 study evaluating casdatifan and cabozantinib in second-line, post-immunotherapy (IO) patients with clear cell renal cell carcinoma (ccRCC).

◦ Entered into a clinical collaboration with AstraZeneca to efficiently evaluate casdatifan in combination with volrustomig, AstraZeneca’s investigational PD-